The site expands Aptar’s manufacturing capabilities to ensure improved manufacturing capacity for pharma customers in Southeast Asia and to offer more innovative product solutions
An image of new Aptar Mumbai site. (Credit: AptarGroup, Inc.)
Aptar Pharma, a unit of US-based Aptar, has opened its new manufacturing site in Mumbai, India to expand production capabilities in Southeast Asia.
Aptar Pharma is engaged in making active material science solutions, drug delivery systems and services.
The new 7,000m2 facility is situated in the Palava Industrial and Logistics Park at Taloja, Mumbai. It has also received ISO 15378 certification.
Aptar Mumbai started its operation in 2012 with the assembly and supply of metered dose valves and pumps.
Its manufacturing capabilities have now been expanded to ensure improved manufacturing capacity for pharma customers in Southeast Asia and to offer more innovative product solutions.
The expansion, which started in early 2022, aligns with Aptar’s localisation strategy. It is also a direct response of the firm to increasing customer demand in the region and part of its global expansion programme.
Aptar Pharma president Gael Touya said: “Our Aptar Pharma business in India has shown robust growth in recent years, and today marks yet another milestone in our investment in the Southeast Asia region.
“Over the past 11 years, Aptar Mumbai has continuously supplied safe, high-quality products that meet even the highest of regulatory requirements.
“This new facility is a key step in serving the needs of our customers in the region, which will ultimately benefit patients.”
According to Aptar Asia president Xiangwei Gong, the new plant will improve local capabilities, enabling the drug delivery system maker to serve its customers with speed and agility.
The Mumbai facility is also expected to support local talent and support the overall growth of the company.
Aptar Southeast Asia Pharma head India president Sanjay Kapote said: “This new site in Mumbai provides a larger space, not only for the expansion of our well-established assembly operations, but also to fuel further localisation and support our vision of bringing in other Aptar Pharma technologies suitable for the Asian market.”